Patented biomarker for cardiac injury. 

Tag: Healthcare economy

cMyC (Cardiac Myosin-binding protein C)
Favourable release kinetics and a higher sensitivity than hs-cTn assays are likely responsible for the better performance in patients presenting early after chest pain onset.
Cardiac myosin-binding protein C (cMyC) is a promising novel biomarker of myocardial injury. Its discovery relied on the characterization of ‘impurities’ detected alongside myosin. cMyC has distinctive release kinetics that should enable it to act as a better adjudicator of acute versus chronic myocardial injury than troponin.
The cMyC test correctly excluded a heart attack in 32 per cent of patients. It could mean thousands of patients are given the all-clear and sent home within quarter of an hour of arriving at A&E. Resulting in cost savings for healthcare.
Switching to cMyC from hs-cTn at King's College London, would yearly save the hospital £800,000 through reduced admissions.
Research related to heart attacks shows that the cMyC test has the potential to reassure many thousands more patients with a single test, freeing up valuable hospital beds in ED / A&E.